177 related articles for article (PubMed ID: 26740054)
21. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Weniger MA; Overbey J; Dunleavy K; Wilson WH; Wiestner A; Parekh S
Oncotarget; 2015 Sep; 6(29):27332-42. PubMed ID: 25714012
[TBL] [Abstract][Full Text] [Related]
22. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
23. Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Sood N; Hamide A; Dubashi B; Nisha Y; Mathaiyan J; Munirajan AK; Ganesn P; Kayal S
Asian Pac J Cancer Prev; 2024 Mar; 25(3):829-837. PubMed ID: 38546066
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
25. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
[TBL] [Abstract][Full Text] [Related]
26. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Savlı H; Galimberti S; Sünnetçi D; Canesastraro M; Palumbo G; Nagy B; Di Raimondo F; Petrini M
Turk J Haematol; 2015 Sep; 32(3):206-12. PubMed ID: 25913414
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
29. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
[TBL] [Abstract][Full Text] [Related]
30. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.
He JQ; Zarnegar B; Oganesyan G; Saha SK; Yamazaki S; Doyle SE; Dempsey PW; Cheng G
J Exp Med; 2006 Oct; 203(11):2413-8. PubMed ID: 17015635
[TBL] [Abstract][Full Text] [Related]
31. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
Front Immunol; 2020; 11():1816. PubMed ID: 32903557
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
33. Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.
Moore CR; Edwards SK; Xie P
J Cancer Sci Ther; 2015 Feb; 7(2):67-74. PubMed ID: 25960828
[TBL] [Abstract][Full Text] [Related]
34. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
Huang Z; Peng S; Knoff J; Lee SY; Yang B; Wu TC; Hung CF
J Biomed Sci; 2015 Jan; 22(1):7. PubMed ID: 25591912
[TBL] [Abstract][Full Text] [Related]
35. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
38. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
40. Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
Gokhale S; Lu W; Zhu S; Liu Y; Hart RP; Rabinowitz JD; Xie P
J Immunol; 2020 Jan; 204(2):459-471. PubMed ID: 31826940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
